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Background: Understanding the role of pre-erythrocytic immune responses to Plasmodium falciparum parasites is
crucial for understanding the epidemiology of malaria. However, published studies have reported inconsistent
results on the association between markers of pre-erythrocytic immunity and protection from malaria.
Methods: The design and statistical methods of studies of pre-erythrocytic immunity were reviewed, and factors
affecting the likelihood of detecting statistically significant associations were assessed. Treatment re-infection
studies were simulated to estimate the effects of study size, transmission intensity, and sampling frequency on the
statistical power to detect an association between markers of pre-erythrocytic immunity and protection from
infection.
Results: Nine of nineteen studies reviewed reported statistically significant associations between markers of
pre-erythrocytic immunity and protection from infection. Studies with large numbers of participants in
high-transmission settings, followed longitudinally with active detection of infection and with immune responses
analysed as continuous variables, were most likely to detect statistically significant associations. Simulation of
treatment re-infection studies highlights that many studies are underpowered to detect statistically significant
associations, providing an explanation for the finding that only some studies report significant associations between
pre-erythrocytic immune responses and protection from infection.
Conclusions: The findings of the review and model simulations are consistent with the hypothesis that
pre-erythrocytic immune responses prevent P. falciparum infections, but that many studies are underpowered to
consistently detect this effect.Background
There are several vaccines targeting the pre-erythrocytic
stages of the Plasmodium falciparum parasite under de-
velopment [1-3] that aim to confer protection by boosting
the pre-erythrocytic (PE) immune response to levels much
higher than observed under conditions of natural expos-
ure, or inducing sterile immunity in malaria naïve in-
dividuals. Recent advances in vaccine development
have led to renewed interest in the PE immune response
[4], both naturally acquired and vaccine-induced. Despite* Correspondence: m.white08@imperial.ac.uk
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reproduction in any medium, provided the orthe considerable progress in the vaccine development ef-
fort, the association between naturally acquired PE im-
mune responses and protection from infection remains
poorly understood.
When a P. falciparum infectious Anopheles mosquito
bites a human, sporozoites are inoculated into the tissue
surrounding the injection site [5], where they migrate to
blood vessels [6] from where they are carried to the liver.
Upon reaching the liver, sporozoites invade hepatocytes,
differentiate into liver-stage parasites and release merozo-
ites into the blood a few days later [7]. The PE immune re-
sponse can prevent successful sporozoite development via
antibody- or cell-mediated responses targeting sporozoite
antigens: the prime targets being circumsporozoite proteintd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and liver-stage antigen 1 (LSA-1) [8]. The mechanisms
underlying antibody-mediated protection include inhib-
ition of hepatocyte invasion, opsonization of sporozoites
for uptake by macrophages and dendritic cells, and pos-
sibly a reduction in the infectious dose of sporozoites [9].
Cell-mediated immunity is provided by CD4+ or CD8+
T-cells, both of which have been observed to elimin-
ate infected hepatocytes in vitro [10,11].
The failure of sporozoite inoculations to consistently
progress to blood-stage malaria has been observed in
both artificial challenge studies [12] and under natural
exposure [13-15]. The proportion of infectious mosquito
bites progressing to blood-stage infection has been
termed the transmission efficiency, and can be defined
at an individual level as the probability that an infectious
bite leads to blood-stage infection, or at a population
level as the proportion of bites on a population that
cause new blood-stage infections. Smith et al. [16]
reviewed studies reporting both the entomological in-
oculation rate (EIR) and the force of infection in chil-
dren and noted that transmission efficiency decreased
with increasing EIR. Several explanations for this effect
have been put forward: heterogeneity in the force of in-
fection [16]; an infection-blocking PE immune response
[17,18]; density-dependent inhibition of sporozoite in-
oculation [19,20]; and inhibition of intrahepatic develop-
ment by blood-stage parasites [21]. In addition, a strong
blood-stage immune response that induces rapid clear-
ance of parasites before detection can be conflated with
a reduction in transmission efficiency [22].
Transmission efficiency is also dependent on age. In
some, but not all, treatment re-infection studies, the time
until detection of infection for adults has been observed
to be significantly longer than for children, suggesting a
reduction in transmission efficiency with age [15,23]. This
effect has been observed despite the fact that mosquitoes
bite adults more often than smaller children because of
their larger surface area [24,25]. Smith [16] explained the
variation in transmission efficiency in young children in
terms of heterogeneity in the force of infection. If biting is
homogeneous then infections are evenly distributed across
the population resulting in a high transmission efficiency.
If instead biting is heterogeneous, then transmission effi-
ciency will be lower as most bites will be concentrated on
highly exposed individuals who are likely to already be
infected [26].
Heterogeneity in exposure, density-dependent inhibition
of sporozoite inoculation and inhibition of intrahepatic de-
velopment by blood-stage parasites cannot explain the dif-
ference in transmission efficiency between children and
adults. The most common explanation for this reduction
in transmission efficiency is the acquisition of PE immunity
with age [17]. However, attempts to quantify the magnitudeof the PE immune response have been complicated by
apparently contradictory results from studies investi-
gating the association between markers of immunity
and protection from infection [27]. For example, the
relationship between naturally acquired anti-CSP anti-
bodies and protection from infection has been found
to be positive [28], negative [29] and non-significant
[30]. In order to explain these observations, a review
of published studies of the relationship between PE
immune responses and protection from infection or
clinical malaria was conducted. The results of these
studies are described in terms of their study design
and sample size. In studies of PE immunity there is
substantial variation in levels of the measured im-
mune marker in the population cohort and hence no
fixed effect size for protection from infection. Therefore
standard methods using sample size calculations to esti-
mate statistical power cannot be applied, necessitating the
use of mathematical models to estimate the statistical
power of studies to measure PE immunity.
Methods
Literature review
A systematic search of the published literature was
undertaken for studies investigating the association be-
tween markers of naturally acquired PE immunity and
protection from malaria (Additional file 1: Table S1).
The search was conducted using the online database
PubMed with the terms “(malaria OR falciparum) AND
(pre-erythrocytic OR infection-blocking)”. The results
were supplemented by iterative reviews of the reference
lists of relevant published papers. The primary aim was
to investigate the association between PE immune re-
sponses and protection from P. falciparum infection.
Each study was classified according to its design. In
cross-sectional studies, participants were tested at the be-
ginning and end of (and sometimes during) a study for
parasitaemia and immune responses. In longitudinal stud-
ies, active detection of infection (ADI) was performed by
testing participants for parasites at a given frequency.
These study designs are summarized in Figure 1. Studies
were further classified according to how immune response
data were analysed, either as a binary variable (e g, high vs
low responders, or sero-positive vs sero-negative), or a
continuous variable (e g, antibody titre). Based on study
design (cross-sectional/longitudinal) and classification of
immune response (binary/continuous), the studies were
classified into four categories.
1. Cross-sectional study with binary immune
response. Participants are split into two categories
according to measured immune responses, and
infection is tested for at at least two cross-sections.
A common study design involves clearing existing
Figure 1 Schematic representation of a treatment re-infection study for measuring pre-erythrocytic immune responses. The solid black
lines denote when samples are taken for a study with two cross-sections, and the dashed lines indicate when additional samples need to be
taken for a longitudinal study. The difference between the cumulative proportion exposed to infection (green) and the cumulative proportion
parasite positive (blue) is explained by pre-erythrocytic immunity and sporozoite inoculations that do not progress to blood-stage infection due
to chance. The difference between the cumulative proportion parasite positive (blue) and the cumulative proportion with clinical malaria (red) is
explained by blood-stage immunity.
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infections a number of weeks later. Tests for an
association between the baseline immune response
and protection from infection are then undertaken.
2. Cross-sectional study with continuous immune
response. Similar to the previous study design
except that immune responses are analysed as a
continuous variable.
3. Longitudinal study with ADI and binary immune
response. Participants are treated to clear existing
infections and followed longitudinally with ADI
at a given frequency. Immune responses,
measured at the beginning of follow up, are used
to classify participants into high and low
categories. Survival analysis is used to test for an
association between immune response and time
to infection.
4. Longitudinal study with ADI and continuous
immune response. Similar to the previous study
design except that immune responses are analysed
as a continuous variable.
There was much variation in the characteristics of the
identified studies, with the most notable differences be-
ing in the endpoint under investigation, the study size
and duration of follow up, the age range of the cohort
and transmission intensity. With such variation in study
characteristics it was not feasible to perform a meta-
analysis of the effects of PE immune responses onprotection from infection and therefore four study de-
signs were simulated to estimate the dependence of stat-
istical power on underlying covariates.Simulation of cross-sectional and longitudinal studies
Simulations were performed to demonstrate the effect of
study size, duration of follow up, and transmission inten-
sity on the statistical power to detect an effect of PE im-
munity. Transmission efficiency can be reduced by PE
immune responses, as measured by some marker α.
Markers of PE immunity can include antibody titre or
measures of cell-mediated immunity such as numbers of
antigen-specific T cells. In the absence of PE immunity,
transmission efficiency was assumed equal to b0. It is as-
sumed that PE immune marker α confers protection from
infection according to an exponential dose–response
curve P αð Þ ¼ e− log 2ð Þ αα50 , where α50 confers 50% protection
[31] (for example the antibody titre required to prevent
50% of infections). The transmission efficiency of a
person with PE immune marker α is then reduced to
b(α) = b0P(α). In a setting with EIR = ε, the force of
infection is Λ(α) = εb0P(α). After clearance of any
existing infection with anti-malarial drugs, the probability
of being re-infected by time t is I(t) = 1 − e− Λ(α)t. The
computer code for simulating this model was written
in R and is included in Additional file 2. The out-
come of a sample simulation, as well as the variation
in antibody titres and force of infection in the study
Table 1 Parameters for simulation of treatment
re-infection studies
Description Parameter Value
Baseline transmission efficiency b0 0.55
PE marker needed to prevent 50% of infections α50 1
Mean in population with 30% protection μα 0.56
Mean in population with 50% protection μα 1.19
Coefficient of variation in PE marker σα/μα 0.75
Duration of follow-up (weeks) T 12
Low transmission EIR (ibppy) ε 5
High transmission EIR (ibppy) ε 150
Baseline transmission efficiency based on estimates from Smith et al. [16].
Pre-erythrocytic immune markers are given in arbitrary dimensionless units
and are assumed to be Log-Normally distributed across a population.
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used for the simulations are given in Table 1.
There are a number of limitations to this model. It is
assumed that the force of infection is homogenous but
the simulations can be adapted to incorporate heteroge-
neous biting. For simplicity, it is assumed that parasites
are not cleared before detection, and submicroscopic in-
fections and issues of sensitivity and specificity are ig-
nored. These complexities are likely to further increase
the uncertainty in identifying a significant relationship
between immune markers and protection.
Estimation of statistical power to detect the effect of
pre-erythrocytic immunity
The effects of PE immunity in two hypothetical popula-
tions are considered, where a measured PE immune re-
sponse causes an average 30 or 50% reduction in the
force of infection compared to a population with no PE
immunity (Table 1). Although the exact proportion of
infections prevented by PE immune responses will be
unknown prior to a study, these effect sizes covered a
range of previously reported effect sizes [32]. Two trial
designs are considered: a longitudinal study with weeklyFigure 2 Simulated longitudinal study for evaluation of the associatio
antibodies. It is assumed that 50 volunteers are followed for 12 weeks wit
titres in the study cohort, split into high (blue) and low (red) responders. (B
of being protected by antibodies. (C) Distribution of transmission efficiency
responders. (D) Sample Kaplan-Meier curves for high and low responders. T
for the KM curves of low and high responders, respectively. The substantia
power to differentiate between high and low responders.ADI for 12 weeks, and a cross-sectional study with
cross-sections at the time of parasite clearance and
12 weeks later. The simulated data were analysed using
Cox proportional hazards for time to infection in longi-
tudinal studies with ADI, or logistic regression for the
outcome (infected/not infected) in cross-sectional stud-
ies. Some 10,000 simulations were performed and then between protection from infection and pre-erythrocytic
h active detection of infection. (A) Log-normal distribution of antibody
) Dose–response curve used in model simulations for the probability
in the study population, split into high (blue) and low (red)
he red and blue shaded regions represent 95% confidence intervals
l overlap between the shaded regions illustrates the low statistical
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studies observing a statistical association between the PE
immune marker and protection at the 5% significance
level.
For the studies of the association between protection
from infection and PE immunity identified in the sys-
tematic review, key design characteristics were recorded
(Additional file 1: Table S1). The power of these studies
to detect a statistically significant effect of a PE immune
response preventing 30 or 50% of total infections in
a population was estimated using simulations that
matched the following study design characteristics:
study size, duration of follow up, sampling frequency
and estimated EIR.
Results
Review of studies of pre-erythrocytic immune responses
Nineteen studies of the association between markers of
PE immunity and protection from infection were identi-
fied (Additional file 1: Table S1). Fifteen studies investi-
gating the association between PE antibodies and
protection from infection were identified; three of eleven
found a statistically significant association between anti-
CSP antibodies and protection at the 5% level. No stud-
ies found statistically significant associations between
anti-TRAP or anti-LSA1 antibodies and protection. One
study found a marginally significant association for anti-
LSA1 antibodies [33], however this is likely due to cor-
relation with other immune responses as LSA-1 epitopes
are only expressed after hepatocyte invasion, at which
stage immunoglobulin G (IgG) antibodies cease to be ef-
fective [34]. One of one studies found a statistically sig-
nificant association between antibodies to multiple
antigens and protection. Of the three studies detecting
a significant association between PE antibodies and
P. falciparum infection, two found antibodies to be asso-
ciated with protection [32,35], and one found antibodies
to be a risk factor for infection [29].
Eight studies investigating the association between
cell-mediated immune (CMI) responses and protection
were identified: One of two found a statistically signifi-
cant association between CSP-specific CMI responses
and protection, one of one found a statistically signifi-
cant association between TRAP-specific CMI responses
and protection, and two of four found a statistically
significant association between LSA1-specific CMI re-
sponses and protection. One of one found a statistically
significant association between combined CSP, TRAP
and LSA1-specific CMI responses and protection. Of the
eight studies detecting a significant association between
markers of cell-mediated immunity and infection, five
found these markers to be associated with protection,
and one was found to be a risk factor for infection
(Additional file 1: Table S1).Simulated effect of study design on statistical power
The results of simulations to estimate the probability of
detecting the effect of PE immunity at the 5% signifi-
cance level are shown in Figure 3. Statistical power in-
creases with study size, and there is a higher probability
of detecting an effect if antibodies confer 50% protection
from infection than if they confer 30% protection. Fur-
thermore, greater statistical power is expected in high
transmission settings (i e, with greater frequency of out-
come) with studies implementing longitudinal follow up
with ADI rather than a single cross-sectional survey at
12 weeks A cross-sectional design is expected to have
lower statistical power in high transmission settings as it
is likely that most participants will become infected be-
tween the baseline and final surveys.
Even with a longitudinal design utilizing a continuous
measure of immunity, studies with 50 individuals have
approximately 10% power to detect 30% protection
against infection in low transmission settings (Figure 3A)
and approximately 40% power in high transmission set-
tings (Figure 3B). Even for a larger effect size where 50%
of infections are prevented, a study of 50 individuals
would be underpowered in a low transmission setting
(Figure 3C). The simulation results suggest that cross-
sectional surveys are underpowered to detect any likely
association between immune responses and protection
from infection except if the effect size is large (50% or
more), the study is undertaken in a large population in a
high transmission setting, and the immune response is
considered as a continuous variable.
Figure 4 shows the statistical power of a longitudinal
study with 50 participants as a function of sampling fre-
quency. In a low transmission setting, the benefit of
sampling more frequently than every six weeks is negligible
as little additional information is obtained by testing volun-
teers who are unlikely to become infected (Figure 4A). In a
high transmission setting, statistical power increases with
increased sampling frequency (Figure 4B). As power in-
creases slowly with sampling frequency, it may be most ef-
ficient to sample fortnightly or monthly if that would allow
more volunteers to be recruited. In more intense transmis-
sion settings where all volunteers are likely to become
infected, sampling frequency will need to be increased to
accurately measure the time to re-infection.
In the studies reviewed, the time of infection is com-
monly assumed to be the time of detection by ADI,
potentially introducing bias in the reduction in the
hazard of infection with increased levels of PE im-
munity (Figures 4C and 4D). Increasing the sampling
frequency will reduce this bias, although interval-
censoring methods can be employed to correct for it. In
low transmission settings where few participants are
infected, this effect is limited (Figure 4C). However, in
high transmission settings this can be appreciable if the
Figure 3 Probability of observing a statistical association at the 5% significance level between a pre-erythrocytic immune response
and protection from infection. (A) A study in a low transmission setting (EIR = 5) where 30% of infections are prevented by pre-erythrocytic
immunity. (B) A study in a high transmission setting (EIR = 150) where 30% of infections are prevented by pre-erythrocytic immunity. (C) A study
in a low transmission setting (EIR = 5) where 50% of infections are prevented by pre-erythrocytic immunity. (D) A study in a high transmission
setting (EIR = 150) where 50% of infections are prevented by pre-erythrocytic immunity.
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optimal sampling frequency will depend on study size and
duration, the expected magnitude of the immune response
under investigation, transmission intensity and seasonality,
the cost of processing samples and the need to avoid tak-
ing too many samples from any one person.
Estimated statistical power of studies for measuring PE
immune responses
For the studies of the association between PE immune
responses and protection from infection identified in the
systematic review, model estimates of the statistical
power at the 5% significance level to detect the effect of
a PE immune response that prevents either 30 or 50% of
infections were calculated (Additional file 1: Table S1).
On average, studies reporting significant associations be-
tween PE immune responses and protection from infec-
tion had higher estimated power than studies not
reporting significant associations (Figure 5A). Studies of
antibody responses had higher estimated power than
studies of CMI responses (Figure 5B), despite the fact
that a higher proportion of studies of cellular immunity
detected statistically significant associations than studies
of antibodies (5/8 vs 3/15). The higher proportion of sig-
nificant results in studies with lower estimated powersuggests that cellular responses have a more important
role in preventing infections than antibody responses
[18].
Analysis of the estimated statistical power of the stud-
ies identified in the review demonstrates that larger
studies were more likely to return significant results
than smaller studies (Figure 5C), and that studies in high
transmission settings were more likely to detect signifi-
cant associations than studies in low transmission set-
tings (Figure 5D). Studies where immune responses were
analysed as binary variables had greater estimated power
than studies where responses were analysed as continuous
variables, although there was much variation (Figure 5E).
This result can be explained by the fact that studies with
binary immune responses had larger numbers of partici-
pants than studies with continuous immune responses. Fi-
nally, studies with longitudinal follow up with ADI had
greater estimated power than cross-sectional studies with-
out ADI (Figure 5F).
Discussion
The PE immune response constitutes the first line of de-
fence against the P. falciparum parasite, and will impact
upon malaria transmission, the incidence of clinical mal-
aria, and the efficacy of infection-blocking vaccines.
Figure 4 The effect of sampling frequency (weeks between each evenly spaced sample assuming no seasonality in transmission) on
statistical power and estimated hazard ratio. Statistical power at the 5% significance level to detect the effect of a pre-erythrocytic immune
response that prevents 50% of infections in (A) a low transmission setting (EIR = 5), and (B) a high transmission setting (EIR = 150). Mean of
estimated hazard ratios for infection associated with a ten-fold increase in antibody titre in (C) a low transmission setting (EIR = 5), and (D) a high
transmission setting (EIR = 150).
Figure 5 Effect of different factors on the estimated statistical power to detect a pre-erythrocytic immune response that prevents 50%
of infections for the study designs identified in the systematic review. (A) Studies reporting statistically significant associations had higher
estimated power than studies not reporting significant associations. (B) Studies of antibody responses had greater estimated power than studies
of cellular responses. (C) Large studies (≥100 participants) had greater estimated power than small studies (< 100 participants). (D) Studies
undertaken in high transmission settings (≥10 ibppy) had greater estimated power than studies undertaken in low transmission settings
(< 10 ibppy). (E) Studies where the immune response was analysed as a binary variable had greater estimated statistical power than studies
where responses were analysed as continuous variables. This result can be explained by the fact that studies with binary immune responses had
larger numbers of participants than studies with continuous immune responses. (F) Studies with longitudinal follow up with active detection of
infection (ADI) had greater estimated power than studies without ADI.
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magnitude of the PE immune response remains poorly
characterized and poorly quantified. In particular, identi-
fying immune responses that significantly correlate with
protection from infection has been difficult due to the
low statistical power of treatment re-infection studies.
Analysis of results from the literature demonstrates that
the majority of studies failed to detect significant associ-
ations between PE immune responses and protection
from infection. One interpretation of these findings is
that PE immunity does not cause a meaningful reduction
in P. falciparum infections. An alternative explanation is
that PE immune responses prevent infections, but that
studies are underpowered to consistently produce statisti-
cally significant findings. The results of model simulations
demonstrates that increasing study size, undertaking stud-
ies in high transmission settings, implementing longitu-
dinal follow-up with ADI, and analysing immunological
data as a continuous variable will improve the probability
of detecting an association between markers of PE im-
munity and protection from infection, if indeed such an
association exists.
None of the studies identified in the review contained
an estimate of statistical power, an important statistic for
interpreting the results of epidemiological studies. De-
signing a study to investigate immune responses can be
viewed as an optimization problem with the aim of
maximizing the statistical power to detect an effect, and
ensuring the effect size is estimated correctly, given real
world limitations on time and resources. There will be
trade-offs between the number of volunteers recruited,
the sampling frequency, the duration of follow up, and
the number of immune responses measured. The op-
timal study design will depend on numerous local
characteristics such as seasonality and the age of partici-
pants, but in general, statistical power can be maximized
by increasing the number of study participants, and
performing the study in a high transmission setting. The
least expensive thing to do to maximize statistical power
is to fully utilize the immune response data by analys-
ing it as a continuous rather than binary variable. Im-
munological data are often non-linearly associated with
protection [36] so it may be beneficial to transform them
before undertaking statistical analysis. Standard statistical
methods such as logistic regression (for cross-sectional
data) and proportional hazards methods (for longitudinal
data) provide a convenient statistical framework for inves-
tigating the association between PE immunity and protec-
tion from infection, as it is straightforward to include
interactions between multiple immune responses and
to adjust for confounders such as LLIN use, age and
location [37,38].
Longitudinal studies have advantages over cross-
sectional studies in that they allow estimation of theincidence of infection and disease as opposed to just
prevalence, and hence allow inferences of causality. Lon-
gitudinal studies also have greater statistical power than
cross-sectional studies since they measure both who be-
comes infected and estimate the time of infection. In-
creasing the sampling frequency for ADI will increase
statistical power but must be balanced by the cost of
additional sampling. Most of the published longitudinal
studies reviewed here performed survival analysis using
the date of sampling when parasites were detected as the
time of infection. However the true time of infection will
have occurred at some time between the first positive
sample and the previous negative sample. This approxi-
mation of the infection time results in biased estimates
of the reduction in infections attributable to PE immune
responses and can be corrected for by using interval-
censored analysis to allow for the unknown infection
time between consecutive samples.
One difficulty in investigating the association between
individual immune responses and protection from malaria
is that multiple immune responses can act cooperatively.
A PE immune response to malaria is likely to be com-
prised of both antibody- and cell-mediated responses di-
rected against multiple parasite antigens [39]. These
responses are likely to be correlated as the acquisition of
immunity depends on malaria exposure. Thus, if only a
single immune response is measured, it may be acting as a
marker for the entire immune response. Measuring mul-
tiple immune responses allows a more detailed investiga-
tion of the association between immunity and protection
from malaria [32,40]. However, even if multiple responses
are measured, protection may still be conferred via some
other undetected immune response correlated with the
measured response. A potential solution may be to use
protein array analysis where plasma from individuals
exposed to malaria is tested against a large proportion
of the P. falciparum proteome [39,41], although this
approach introduces additional difficulties due to mul-
tiple comparisons.
A second difficulty encountered in field studies is that
immune responses can act as markers of exposure as
well as correlates of protection [42] – as was seen when
antibodies were found to be associated with protection
in some studies and increased risk of infection in others.
Heterogeneity in exposure will lead to heterogeneity in
the rate of acquisition of immunity, with individuals
under the most intense exposure developing the stron-
gest immune response. Individuals identified as having a
strong immune response may be at increased risk of
future infection compared to the rest of the cohort as
their increased exposure may outweigh the benefits of
the stronger response. This phenomenon may lead to a
study identifying protective antibodies as a risk factor
for future infection [38].
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responses to act as markers for exposure, and the possi-
bility of correlation between multiple immune responses
constitute limitations to the model used for the estima-
tion of statistical power, and hence the results presented
here. A constant force of infection was assumed, which
equates to an exponential distribution for time to re-
infection. The model may also be adapted to capture
seasonality in transmission and hence better reflect real
world conditions. Time-dependent covariates may be
used to test for a changing effect over time. Further-
more, if multiple measures of PE immune response are
available at different time points then they may be
analysed as time-dependent covariates, as markers of
naturally-acquired immunity measured at baseline may
not correlate well with the risk of infection in the latter
part of the study, as several reports indicate naturally ac-
quired P. falciparum specific responses are relatively
short-lived [43,44]. The assumption of a constant force
of infection in proportional hazards models is violated
by the heterogeneous distribution of infectious bites.
Unaccounted heterogeneity in the force of infection can
lead to biased estimates of the hazard rate [26], although
this can be ameliorated by using survival analysis
methods incorporating a frailty distribution to account
for unmeasured heterogeneity.
Conclusion
The results of studies to investigate the association be-
tween markers of PE immunity and protection from in-
fection have often been inconclusive due to sub-optimal
study design. The power to detect an effect of a PE im-
mune response can be increased by increasing study
size, undertaking studies in high transmission settings,
performing longitudinal follow up with ADI and analys-
ing immune responses as a continuous variable.
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